Posted in | Nanomedicine

Celator to Present Data on CombiPlex Technology Platform Applied to MTA Drug Combinations at AACR-NCI-EORTC 2015

Celator Pharmaceuticals, Inc. today announced that data from applying the CombiPlex® technology platform to drug combinations incorporating molecularly targeted agents (MTAs) will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA on November 5-9, 2015.

CombiPlex is well-positioned to address the challenges with the development of combination drug candidates.  Nano-scale delivery systems coordinate the pharmacokinetics (PK) of drug combinations after administration so that the optimal ratio of the two drugs is exposed to tumor cells for prolonged times while reducing drug exposure and toxicity to normal tissues.

Celator is applying this technology to create new drug combinations that target pathways associated with tumor cell growth and/or resistance to treatment.  Such MTAs are being widely pursued with an increasing focus on combining agents that target multiple cellular pathways in order to improve therapeutic responses.

Celator's efforts have focused on two combinations: the heat shock protein 90 inhibitor AUY922 combined with docetaxel and the MEK inhibitor selumetinib combined with the Akt inhibitor ipatasertib.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback